EGFR and diffuse astrocytoma: The cIMPACT-NOW update 6 has proposed to reclassify isocitrate dehydrogenase 1/2 wildtype (IDHwt) diffuse astrocytomas as glioblastoma if they present with either (1) telomerase reverse transcriptase (TERT) promotor mutation (pTERTmut); (2) epidermal growth factor receptor (EGFR) gene amplification; or (3) whole chromosome 7 gain and whole chromosome 10 loss (+ 7/− 10) [2].